Fintel reports that on April 22, 2025, Cantor Fitzgerald initiated coverage of Vaxcyte (NasdaqGS:PCVX) with a Overweight ...

In a volatile market, growth stocks may seem like the least attractive options. That is because growth stocks are shares of ...

This downside came after Vaxcyte reported mixed results from a phase II study on its investigational pneumococcal conjugate vaccine (PCV ... from $2.94 to $2.15. 89bio’s earnings missed ...

Shares of Sanofi have rallied 15% year to date compared with the ... in phase III development include a 21-valent pneumococcal conjugate vaccine and a next-generation rabies vaccine.

Vaxcyte PCVX is a clinical-stage biotech focused on developing vaccines to prevent or treat bacterial infectious diseases. In ...

These findings provide mechanistic evidence linking neonatal antibiotic exposure to impaired vaccine immunogenicity via ...

Babies treated with antibiotics in the first few weeks of their life are likely to show weaker immune responses to essential ...

For other vaccine antigens, namely, certain PCV and pertussis vaccine antigens ... antibodies Intergroup ratio 0.5 Hib conjugate 0.15 μg/mL % of subjects with anti-PRP antibodies ≥0.15 μg ...

Results from the study include: In cohort 1, CAPVAXIVE elicited OPA responses that were comparable to PCV15 for the 6 common serotypes, and higher for the 15 unique serotypes and serotype 15B ...